Message of
from CEO

When I was appointed the CEO of Aché in March 2023 I had the great satisfaction of joining a Company that has the noble purpose of bringing more life to people, wherever they are.

On this journey the Company had a positive impact on the lives of 88 million people in 2022 and supported the work of more than 220 thousand doctors.

In this report I present the main achievements of the 2022 financial year, which are reflected in growth that generated value for people, for nature, and for the business.

Considering society’s current challenges the culture of the organization and its vision of sustainability evolved from the Company’s strategic ambition.

The results we achieved prove that our drivers and the strategic decisions we took were correct. Net revenue increased by 23.6% compared to 2021, net income was BRL 1.058 billion, an increase of 62.4%, while our EBITDA reached BRL 1.4 billion, a margin of 28.5%, and an evolution of 35.3% in relation to the previous year. Our share of the Brazilian pharmaceutical market reached 6.1% last year.

One of the Company’s main assets, our Care for Life Relationship Programsurpassed the mark of 21 million patients benefited, and more than 9 million units of medicine sold to 30,000 accredited pharmacies in Brazil.

The satisfaction index (NPS) with the Care for Life Program is 97.1%.

The result of an aspiration that was established when formulating our strategic plan, the Longevity Project is backed by scientific knowledge and a wide range of therapeutic solutions that are designed to meet the needs of an increasingly longlived population and enable it to age in a healthy manner whether with regard to the treatment or prevention of chronic diseases.

The launch of PEAS – Excellence Program in Shopper Service, estruturado para maximizar a satisfação do shopper na experiência de compra de medicamentos sob prescrição, consiste em mais uma iniciativa de entrega de valor aos clientes.